中国工程院院士、中国微循环学会理事长詹启敏在揭牌仪式上表示，中心的设立将有助于进一步集 聚学会顶尖的专家资源与前沿科技成果，助力苏州在微循环相关疾病防治、高端医疗器械研发、慢病管 理体系优化等领域，实现技术突破与产业升级，从而优化区域创新生态，显著提升"科创中国"在苏州的 示范引领效应。 中国微循环学会自1993年成立以来，长期深耕微循环领域的学术研究、临床转化与产教融合，在心 脑血管疾病、糖尿病并发症、肿瘤微环境、组织工程等前沿领域拥有深厚学术积累和丰富专家资源。今 年以来，学会已积极组织60余名理事专家，与苏州39家生物医药企业、24家科研院所及医院进行精准对 接，目前已达成15项合作意向，并深入走访10家本地企业提供专业技术指导。 该中心在中国科协"科创中国"工作统一部署下，由苏州市科学技术协会、中国微循环学会及东南大 学苏州研究院3方共同推动组建。作为国家一级学会，中国微循环学会秉持"医工结合、产教融合"发展 理念，与苏州全力推进生物医药产业创新集群高质量发展的战略需求及"健康苏州"的建设实践高度契 合。为深化学会在苏州的实体化合作，3方共同签署协议，共建苏州融合发展中心。该中心设立后，将 重点围绕慢 ...

新华社巴黎10月20日电（记者罗毓）很多老年人因年龄相关的黄斑变性逐步丧失视力。法国国家健康与 医学研究院等机构20日表示，研发出一种眼部植入系统，可使80%的患者部分恢复视力。 该系统名为Prima，由一枚视网膜下植入物和一副增强现实眼镜组成。植入物大小为2毫米×2毫米，厚30 微米，需通过手术植入视网膜下方，以替代因疾病而受损丢失的感光细胞。眼镜配备微型摄像头以捕捉 周围影像，并将视频传至随身计算机，由算法对图像进行增强，可将其放大、提升对比度与亮度，随后 把视频转换为红外光束，实时投射到视网膜下植入装置。该装置接收红外信号并刺激邻近神经元，将信 息传至大脑。 共38名患者参与临床研究，他们视力严重受损，难以辨认标准化视力表上的字母，其中32人完成研究。 佩戴Prima一年后，81%的受试者可在视力表上多读至少10个字母；78%的受试者可多读至少15个字 母；效果最好的能多读59个字母。84.4%的受试者表示能够阅读字母、数字和单词。 此外，共在19名受试者中观察到26例严重不良事件，均属风险分析中已预期的情况，包括高眼压、视网 膜下出血等，绝大多数发生在术后两个月内，其中大多数已自行缓解或经医学干预迅速 ...

近日，浙江大学医学院附属邵逸夫医院（下称"浙大邵逸夫医院"）宣布，借鉴牡蛎粘附机制，该院骨科范顺武教 授、林贤丰副主任医师团队，成功研发出全球首款能够在人体血液环境中实现即时强效黏合，并能完全生物降解 的骨胶水材料——"骨02"碎骨黏。 "骨02"命名灵感源于家喻户晓的"502胶水"，研发团队介绍，这一创新生物材料可普遍用于大小骨折碎片的黏合固 定，有望减少或替代传统金属内固定物的使用。 研发团队核心成员林贤丰曾在回老家浙江温州探亲时，注意到粘在跨海大桥底部的牡蛎，这让他深受启发，"既然 牡蛎能在海水中粘得牢固，那么能否在人体湿性环境中创造类似的可能性？" 历经8个月的严谨临床试验研究，浙大邵逸夫医院联合浙大二院、上海六院等国内多家权威医疗机构，成功完成全 球首个针对粉碎性骨折黏合治疗的多中心随机对照临床研究入组治疗，"骨02"在150余例受试患者中展现出良好的 安全性和有效性。 9月28日，研发团队核心成员林贤丰在接受新京报记者专访时提到，骨胶水不仅能解决传统手术"碎骨块复位难"的 问题，更能减少手术创伤、提升治疗效果。 在林贤丰看来，金属固定是"刚性固定"，需要钢板螺钉提供稳定性，这意味着较大的手术切口和 ...

Core Viewpoint - The development of a new bone adhesive material named "Bone 02" by Zhejiang University Shao Yifu Hospital shows promising results in treating comminuted fractures, demonstrating good safety and efficacy in clinical trials involving over 150 patients [1][2]. Group 1: Product Development - The "Bone 02" material was inspired by the biological adhesion mechanism of oysters and underwent over 50 formula iterations and hundreds of tests to overcome key challenges such as biotoxicity and adhesion strength in blood environments [2]. - The maximum adhesive pull force of "Bone 02" can reach over 400 pounds, indicating its potential to replace traditional metal fixation devices while reducing the risk of foreign body reactions and infections [2]. Group 2: Clinical Application - The new adhesive material is applicable for fixing bone fragments of various sizes and can significantly enhance surgical efficiency and reduce trauma during operations, contributing to minimally invasive orthopedic surgeries [2]. - "Bone 02" is expected to be useful in emergency situations such as military operations and disaster rescue, where rapid and effective fracture treatment is critical [2].

Core Viewpoint - The establishment of the Zero Magnetic Interventional Medicine Laboratory at Fudan University Affiliated Pudong Hospital represents a significant advancement in the integration of zero magnetic medicine and advanced interventional medicine, aiming for early non-invasive diagnosis of diseases with high precision and resolution [1][2]. Group 1: Laboratory Establishment and Collaboration - The Zero Magnetic Interventional Medicine Laboratory is led by Fudan University Affiliated Pudong Hospital and integrates resources from several prestigious hospitals and universities, forming a high-level academic team and a complete innovation transformation chain from theoretical research to technology development and industrial application [1]. - A four-party strategic cooperation agreement was signed among Fudan University Affiliated Pudong Hospital, Beihang University Large Scientific Device Research Institute, Hangzhou Weak Magnetic Field National Major Science and Technology Infrastructure Research Institute, and related enterprises [1]. Group 2: Technological Advancements and Research Focus - Academician Fang Jiancheng emphasized that weak magnetic fields are a new scientific discovery that complements structural imaging technologies, aiming to build a comprehensive health detection system for the human body [2]. - The laboratory will focus on the research and development of intelligent zero magnetic interventional materials and devices, establish clinical technical guidelines, and cultivate high-level talent, ultimately creating a national-level center for the promotion and application of zero magnetic interventional medicine technology [2]. Group 3: Future Directions and Benefits - The laboratory aims to enhance the deep research and application promotion of zero magnetic technology in interventional medicine, strengthening interdisciplinary collaboration and results transformation [3]. - The collaboration is expected to provide better early screening and treatment options for cardiac and brain diseases, benefiting a larger population [2].

Core Viewpoint - Huaborn Neutron Technology Co., Ltd. has completed a multi-hundred million RMB Pre-A round financing, indicating strong market confidence in Boron Neutron Capture Therapy (BNCT) as a promising treatment method [2][11]. Company Overview - Established in 2023 and headquartered in Hangzhou, Zhejiang, Huaborn Neutron is a national high-tech enterprise focused on the research, production, and application of accelerator-driven BNCT technology [3]. - The company was founded by Wang Sheng, a renowned neutron scientist, and has assembled a team of experts across various disciplines including nuclear physics, software, control, mechanics, pharmacy, clinical medicine, and materials science [3]. Main Products and Technologies - Huaborn Neutron has developed the HyBorSys® BNCT full-process solution, which includes an accelerator neutron source system, boron drugs, and a treatment planning system (TPS), achieving a complete closed-loop for BNCT technology [4]. - The BNCT equipment utilizes a high-current proton RFQ accelerator and long-life solid lithium target technology, ensuring high power stability and a target lifespan that is globally leading (>1500 mA·h) [6]. - The company has established a research and development system for boron drug synthesis, significantly improving product quality and reducing production costs [7]. - The domestically developed TPS can model based on multi-modal imaging data from patients, simulating dose distribution using Monte Carlo particle transport programs for precise prediction and individualized treatment planning [9]. Current Status and Future Prospects - The HyBorSys® demonstration device has completed medical device registration inspection, and the boron drug is about to enter the IND application stage [10]. - BNCT is recognized as a significant breakthrough in the field of radiotherapy, gradually moving towards clinical application, with Huaborn Neutron achieving independent breakthroughs in devices, drugs, and software within two years [11]. - The recent financing round, attracting several hundred million RMB, reflects the capital market's high recognition of BNCT as a cutting-edge therapy [11].

Employment Market Overview - The employment rate for individuals aged 16-64 in the UK rose to 75.1% from February to April 2025, indicating a positive aspect of the job market [1] - However, the number of salaried employees decreased by 55,000 (0.2%) in March-April 2025 and by 115,000 (0.4%) from April 2024 to April 2025, suggesting a cautious hiring strategy among UK businesses [1][3] Public vs. Private Sector Employment - Public sector employment remained stable at 6.15 million in March 2025, with a year-on-year growth of 0.6%, while private sector employment growth faced different challenges [3] - This disparity provides insights for investors, indicating that stable public sector-related industries may offer defensive investment opportunities, while emerging sectors in the private sector also hold potential [3] Unemployment and Economic Inactivity - The unemployment rate for individuals aged 16 and above reached 4.6% from February to April 2025, showing an increase both year-on-year and quarter-on-quarter, which raises concerns about economic growth [3] - The economic inactivity rate for those aged 16-64 decreased to 21.3%, but a significant portion is attributed to long-term illness and students, highlighting structural issues in the labor market [3] Wage Growth and Job Vacancies - Average wage growth for employees was notable, with regular wages increasing by 5.2% and total wages by 5.3% from February to April 2025, leading to improved consumer purchasing power [4] - Job vacancies fell to 736,000 from March to May 2025, marking a continuous decline over 35 quarters, indicating weakened labor demand and cautious investment in labor-intensive sectors [4] Consumer Sector Opportunities - With rising wages, the consumer sector is expected to experience growth, particularly in mid-to-high-end consumption areas such as premium retail, quality dining, and personalized travel services [5] - UK high-end fashion brands may benefit from increased disposable income, leading to higher sales, while specialty tourism projects and luxury hotels are also likely to gain from the consumption upgrade trend [5] Healthcare Sector Investment Potential - The high proportion of long-term illness in the economically inactive population underscores pressure on the UK healthcare system, presenting investment opportunities in medical device development and biopharmaceuticals focused on chronic disease treatment [6] Education and Training Sector Growth - The shortage of skilled labor in the UK is driving demand for education and training, particularly in vocational skills training and online education platforms, which are poised for significant growth [7] Human Resources Services Demand - Despite an overall decline in job vacancies, there remains a strong demand for high-end and specialized talent recruitment, suggesting that human resources service firms focusing on high-end talent acquisition may thrive [8]

Core Insights - The article provides an overview of the latest trends in investment and financing activities in the domestic market, highlighting key sectors and significant funding events [3]. Group 1: Investment Overview - A total of 66 financing events were disclosed in the domestic primary market this week, a decrease of 36 events compared to the previous week [5]. - Among the disclosed financing events, 21 had reported amounts, with a total financing scale of 4.17 billion RMB, resulting in an average financing amount of 199 million RMB [5]. Group 2: Sector Distribution - The most active sectors in terms of financing events were intelligent manufacturing, artificial intelligence, and healthcare, with 20, 18, and 7 events respectively [7]. - In terms of disclosed financing amounts, artificial intelligence led with a total financing scale of approximately 1.41 billion RMB, highlighted by TARS, an AI-driven embodied intelligence technology company, which completed a $120 million angel round [7][8]. - The healthcare sector followed with a disclosed financing total of 1.32 billion RMB, with Ruiqiao Dingke, a medical device developer in chronic disease management, completing a 1 billion RMB Series A financing [9]. Group 3: Regional Distribution - The disclosed investment events were primarily concentrated in Jiangsu, Guangdong, and Shanghai, with 17, 14, and 11 events respectively [13]. - Jiangsu reported a total financing of 300 million RMB across 3 disclosed events, while Shanghai had 22.92 billion RMB from 7 disclosed events [16]. Group 4: Stage Distribution - The majority of the disclosed investment events were early-stage, with 51 events, followed by 14 growth-stage events and 1 late-stage event [17]. Group 5: Major Financing Events - Significant financing events included Ruiqiao Dingke's Series A round exceeding 1 billion RMB and TARS's angel round of $120 million [22][23]. Group 6: M&A Activity - There were 7 disclosed completed M&A events this week, a decrease of 7 compared to the previous week, with notable transactions including the acquisition of Longsheng New Energy by Saisir for 8.164 billion RMB [42][44].